
Genome editing company CRISPR Therapeutics nets $52mm in IPO
Executive Summary
CRISPR Therapeutics AG (genome editing focused on CRISPR/Cas9-based therapeutics) netted $52mm in its initial public offering of 4mm shares at $14 (down-sized and below the anticipated price range) on the Nasdaq. Concurrently, the company raised $35mm through the sale of 2.5mm shares to development partner Bayer through a private placement offering.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- IPO
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com